Trial Profile
An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Ferring Pharmaceuticals
- 10 Sep 2021 Planned End Date changed from 1 Aug 2021 to 1 Nov 2021.
- 10 Sep 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Nov 2021.
- 22 Apr 2021 Planned End Date changed from 1 Mar 2021 to 1 Aug 2021.